We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.82B
AUM Growth
+$1.31B
Cap. Flow
+$158M
Cap. Flow %
2.03%
Top 10 Hldgs %
19.27%
Holding
869
New
65
Increased
350
Reduced
240
Closed
81

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$43.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$30.4M
3
GILD icon
Gilead Sciences
GILD
+$28.3M
4
BIIB icon
Biogen
BIIB
+$26.7M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$25.2M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$75.2M
2
LOXO
Loxo Oncology, Inc
LOXO
+$28.1M
3
DHR icon
Danaher
DHR
+$27.9M
4
A icon
Agilent Technologies
A
+$26.4M
5
MKC icon
McCormick & Company Non-Voting
MKC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 33.36%
2 Technology 15.96%
3 Financials 11.25%
4 Consumer Discretionary 8.98%
5 Communication Services 7.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WDC icon
551
Western Digital
WDC
$155B
$1.42M 0.02%
39,006
-98,578
-72% -$3.37M
IDXX icon
552
Idexx Laboratories
IDXX
$45B
$1.38M 0.02%
6,174
+250
+4% +$51.6K
HDS
553
DELISTED
HD Supply Holdings, Inc.
HDS
$1.38M 0.02%
31,799
+10,273
+48% +$428K
BLFS icon
554
BioLife Solutions
BLFS
$1.6B
$1.36M 0.02%
76,000
– –
CTAS icon
555
Cintas
CTAS
$86.9B
$1.35M 0.02%
26,816
-8,496
-24% -$411K
RHI icon
556
Robert Half
RHI
$4.19B
$1.35M 0.02%
20,695
+4,197
+25% +$266K
VMC icon
557
Vulcan Materials
VMC
$37.3B
$1.35M 0.02%
11,395
+1,271
+13% +$137K
STAA icon
558
STAAR Surgical
STAA
$1.09B
$1.33M 0.02%
39,000
– –
CPAY icon
559
Corpay
CPAY
$25.2B
$1.33M 0.02%
5,402
+473
+10% +$102K
FRT icon
560
Federal Realty Investment Trust
FRT
$11B
$1.33M 0.02%
9,638
+245
+3% +$32.1K
AORT icon
561
Artivion
AORT
$1.33B
$1.31M 0.02%
45,000
– –
SONY icon
562
Sony
SONY
$133B
$1.31M 0.02%
155
+80
+107% +$749
FOXA icon
563
Fox Class A
FOXA
$24.4B
$1.3M 0.02%
+35,343
New +$1.38M
NOV icon
564
NOV
NOV
$7.2B
$1.29M 0.02%
48,528
+905
+2% +$25.7K
PNR icon
565
Pentair
PNR
$10.6B
$1.29M 0.02%
29
-16
-36% -$666
LW icon
566
Lamb Weston
LW
$7.4B
$1.29M 0.02%
17,201
– –
EQNR icon
567
Equinor
EQNR
$90.9B
$1.27M 0.02%
+58
New +$1.3K
JKHY icon
568
Jack Henry & Associates
JKHY
$11.2B
$1.25M 0.02%
9
+1
+13% +$132
CIT
569
DELISTED
CIT Group Inc.
CIT
$1.25M 0.02%
25,974
+5,435
+26% +$256K
LII icon
570
Lennox International
LII
$19.2B
$1.24M 0.02%
4,695
+600
+15% +$143K
HACK icon
571
Amplify Cybersecurity ETF
HACK
$2.67B
$1.24M 0.02%
30,885
+8,085
+35% +$308K
SRRA
572
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.23M 0.02%
18,000
– –
CALA
573
DELISTED
Calithera Biosciences, Inc
CALA
$1.21M 0.02%
9,000
– –
EGRX
574
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$1.21M 0.02%
24,000
– –
BBD icon
575
Banco Bradesco
BBD
$38.8B
$1.21M 0.02%
177,118
-10,858
-6% -$78.1K
21 22
23
24 25

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q1 2019 Portfolio in Review

As of Q1 2019, Candriam SCA held 869 positions worth $7.82B, up 20% from $6.51B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Candriam SCA's Q1 2019 filing shows 65 new, 350 increased, 240 reduced and 81 closed positions. Its largest new stake was Baozun: 640,000 shares worth $26.6M. The largest sale was Celgene Corp, an estimated $75.2M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 35% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q1 2019 buy was Baozun: 640,000 shares worth $26.6M.
  • Candriam SCA added most to Merck in Q1 2019, an estimated $43.7M increase.
  • Candriam SCA's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $75.2M.
  • Candriam SCA fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $28.1M.
  • Candriam SCA's ten largest holdings make up 19% of its $7.82B portfolio in Q1 2019.
  • Candriam SCA opened 65 new positions and closed 81 in Q1 2019.
  • Candriam SCA's portfolio value rose 20% quarter-over-quarter to $7.82B.

Based on Candriam SCA's 13F filing for Q1 2019, filed 2 May 2019.